Zura Bio reports Q2 2026 results, completes enrollment in two tibulizumab trials
The company finished enrollment ahead of target in both mid-stage tibulizumab studies and plans a third trial in polymyalgia rheumatica by year-end 2026.
SEC filing
Latest
1 story